Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216703 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
A Phase 3 study of Cervical Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,023
- Enrollment target
- 20
- Study locations
NCT07216703 is a Phase 3 study of Cervical Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,023 participants, above the 563-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT07216703, a Phase 3 study of Cervical Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,023 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Cisplatin
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- BIOLOGICAL Sacituzumab Tirumotecan
Study Locations (20)
Quebec
- Centre Hospitalier de l'Université de Montréal ( Site 0616) - Montreal
- McGill University Health Centre ( Site 0602) - Montreal
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0611) - Québec
Santa Fe Province
- Instituto de Oncologia de Rosario ( Site 0104) - Rosario
- Hospital Provincial del Centenario ( Site 0106) - Rosario
Moravskoslezský kraj
- Nemocnice AGEL Novy Jicin a.s. ( Site 1004) - Nový Jičín
- Fakultni nemocnice Ostrava ( Site 1005) - Ostrava
Florida
- Mount Sinai Comprehensive Cancer Center ( Site 6000) - Miami Beach
Louisiana
- TRIALS 365 ( Site 6008) - Shreveport
Nevada
- Women's Cancer Center of Nevada ( Site 6011) - Las Vegas
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) - New York
Tennessee
- University of Tennessee Medical Center ( Site 6012) - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,023 participants |
| Start Date | 2026-01-19 |
| Est. Completion | 2031-10-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216703
The ClinicalTrials.gov registry entry for NCT07216703 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,023 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 563-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07216703 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Quebec, Santa Fe Province, Moravskoslezský kraj.
Frequently Asked Questions
What is clinical trial NCT07216703 about?
NCT07216703 is a clinical study titled "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)". Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumoteca...
What is the current status of trial NCT07216703?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,023 participants. The study started on 2026-01-19. Estimated completion is 2031-10-29.
What conditions does trial NCT07216703 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT07216703?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cisplatin (DRUG), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Sacituzumab Tirumotecan (BIOLOGICAL).
Who is sponsoring clinical trial NCT07216703?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216703 being conducted?
This trial has 20 study locations across Florida, Louisiana, Nevada, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
RECRUITING · Phase 3
-
Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix
COMPLETED · Phase 3
-
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
COMPLETED · Phase 3
-
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 3
-
Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer
COMPLETED · Phase 3
-
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.